Lilly-backed Absci secures $100 million financing to advance endometriosis and pattern hair loss programs

Absci, the biotech backed by Eli Lilly, has raised $100 million to drive the next stage of development for a therapy aimed at endometriosis and pattern hair loss, according to a report published Monday by Pharmaceutical Technology.

The company’s announcement comes around the same time it highlighted “positive Phase I data,” a milestone that typically indicates early evidence of safety and preliminary activity in humans before a program can move to larger, later-stage studies. The report frames the funding as a way to keep momentum as the lead asset progresses through the clinical pipeline.

Endometriosis, where tissue similar to the uterine lining grows outside the uterus, can cause chronic pain and can be difficult to manage with existing medicines. Pattern hair loss, also known as androgenetic alopecia, affects a large portion of the population and has attracted sustained pharmaceutical development, even as outcomes can vary and treatment often requires ongoing use.

In its update, Absci tied the financing to advancing work in both indications. While the report does not describe the scientific mechanism, the therapy’s dual focus suggests the company intends to evaluate its approach across different patient populations and disease endpoints rather than limiting development to a single market.

The $100 million amount, as described in the report, is significant for a clinical-stage biotech because it can be used to fund manufacturing for trial dosing, support additional study sites, and pay for the staff and regulatory work needed to transition from early-stage data to later clinical phases. However, the post does not provide a breakdown of how much will be allocated to endometriosis versus hair loss, nor does it specify whether additional candidates are planned beyond the lead program.

Eli Lilly’s backing is relevant because it indicates continued interest by a major drugmaker in platform-based biotechs that can produce candidates efficiently and advance them into clinical testing. For investors, a large strategic-backed financing can also reduce near-term dilution risk compared with smaller rounds, though that depends on the terms, which were not detailed in the report.

The company did not disclose, in the information cited by Pharmaceutical Technology, the exact structure of the financing, the investors involved, or the valuation implied by the round. It also did not provide details on the Phase I study design, including patient numbers, dosing schedule, endpoints reported, or duration of follow-up, all of which are crucial for interpreting how strong the early results may be.

Looking ahead, the key question for Absci’s program will be how the company translates the reported Phase I indicates into subsequent evidence. As it moves forward, market participants will likely focus on whether later-phase studies confirm efficacy in endometriosis and pattern hair loss, and whether safety observations remain stable as patient numbers increase. Updates on trial design, readouts, and timelines will also matter because those items determine how quickly the therapy can reach regulatory review.